Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Palena Therapeutics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which is the total number of active matters currently facing the company. This volume indicates a focused prosecution phase where the company is engaged with the patent office on a specific application.
The prosecution of this portfolio is highly concentrated, involving 1 distinct examiner and 1 distinct art unit. This means that the active matter is being reviewed by a single individual within a specialized unit. For practitioners, this suggests that the outcome of the company's current patent efforts is entirely dependent on the review of this specific examiner.
JOHNSON, TIRONE DEREK is the busiest examiner for Palena Therapeutics Inc., holding 1 busiest examiner pending action. Because this busiest examiner pending count matches the total pending office actions of 1, this individual is responsible for the entirety of the company's current workload. The alignment of the 1 distinct art unit with this single examiner further emphasizes the localized nature of the company's active patent prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035837 | COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE | JOHNSON, TIRONE DEREK | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035837 | COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Final Rejection | 46d overdue | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial